pantoprazole has been researched along with Liver Diseases in 3 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dabigatran etexilate is an orally administered prodrug, which is rapidly absorbed and converted to the active form, dabigatran." | 2.44 | Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. ( Stangier, J, 2008) |
| " If two drugs of the same class have a similar dose-efficacy profile, then the favourable/unfavourable balance of the pharmacokinetic characteristics of the drugs may determine the drug of choice." | 2.39 | Pharmacokinetics--a relevant factor for the choice of a drug? ( Benet, LZ; Zech, K, 1994) |
| "Pantoprazole was well tolerated." | 1.31 | Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. ( Abell, M; Ferron, GM; Getsy, J; Mayer, P; Noveck, RJ; Paul, J; Pockros, P; Preston, RA; Turner, M, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stangier, J | 1 |
| Benet, LZ | 1 |
| Zech, K | 1 |
| Ferron, GM | 1 |
| Preston, RA | 1 |
| Noveck, RJ | 1 |
| Pockros, P | 1 |
| Mayer, P | 1 |
| Getsy, J | 1 |
| Turner, M | 1 |
| Abell, M | 1 |
| Paul, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Rabeprazole-induced Elevated Gastric pH on APO-Dabigatran Exposure in Healthy Volunteers[NCT04157881] | Phase 4 | 46 participants (Actual) | Interventional | 2020-01-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pantoprazole and Liver Diseases
| Article | Year |
|---|---|
Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Anticoagulants; Benzimidazoles; | 2008 |
Pharmacokinetics--a relevant factor for the choice of a drug?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aging; Benzimidazoles; Biological Ava | 1994 |
1 other study available for pantoprazole and Liver Diseases
| Article | Year |
|---|---|
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Dose-Response Rela | 2001 |